Gastrointestinal changes associated to heart failure

dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:26:23Z
dc.date.available2014-05-27T11:26:23Z
dc.date.created2014-05-27T11:26:23Z
dc.date.issued2012-03-01
dc.identifierArquivos Brasileiros de Cardiologia, v. 98, n. 3, p. 273-277, 2012.
dc.identifier0066-782X
dc.identifier1678-4170
dc.identifierhttp://hdl.handle.net/11449/73211
dc.identifier10.1590/S0066-782X2012000300011
dc.identifierS0066-782X2012000300011
dc.identifier2-s2.0-84860335428
dc.identifier2-s2.0-84860335428.pdf
dc.identifier1590971576309420
dc.identifier4463138671998432
dc.identifier5016839015394547
dc.description.abstractOver the last decade, several studies were conducted on the gastrointestinal changes associated to chronic heart failure. This article presents a literature review on the physiopathology and clinical consequences of pathological digestive changes of heart failure patients. Structural and functional abnormalities of the gastrointestinal tract, such as edema of absorptive mucosa and intestinal bacterial overgrowth, have been leading to serious clinical consequences. Some of these consequences are cardiac cachexia, systemic inflammatory activation and anemia. These conditions, alone or in combination, may lead to worsening of the pre-existing ventricular dysfunction. Although currently there is no therapy specifically earmarked for gastrointestinal changes associated to heart failure, the understanding of digestive abnormalities is germane for the prevention and management of systemic consequences.
dc.languageeng
dc.relationArquivos Brasileiros de Cardiologia
dc.relation1.318
dc.rightsAcesso aberto
dc.sourceScopus
dc.subjectAbnormalities of the digestive system
dc.subjectAnemia
dc.subjectCachexia
dc.subjectHeart failure/complications
dc.subjectIntestinal absorption
dc.subjectacetylcysteine
dc.subjectbacterium lipopolysaccharide
dc.subjectdiuretic agent
dc.subjectendotoxin
dc.subjectetanercept
dc.subjectimmunoglobulin
dc.subjectinfliximab
dc.subjectinterleukin 1 receptor blocking agent
dc.subjectinterleukin 10
dc.subjectiron
dc.subjectmethotrexate
dc.subjectmitogen activated protein kinase p38 inhibitor
dc.subjectpentoxifylline
dc.subjectthalidomide
dc.subjecttumor necrosis factor alpha
dc.subjecttumor necrosis factor alpha converting enzyme inhibitor
dc.subjectanemia
dc.subjectbacterial overgrowth
dc.subjectcachexia
dc.subjectdiet therapy
dc.subjectedema
dc.subjectexercise
dc.subjectgastrointestinal absorption
dc.subjectgastrointestinal change
dc.subjectgastrointestinal disease
dc.subjectheart failure
dc.subjectheart ventricle function
dc.subjecthuman
dc.subjectimmunomodulation
dc.subjectinflammation
dc.subjectintestine flora
dc.subjectintestine mucosa permeability
dc.subjectiron deficiency
dc.subjectpathophysiology
dc.subjectreview
dc.subjectstomach antrum vascular ectasia
dc.subjectstomach mucosa
dc.subjecttelangiectasia
dc.subjectGastrointestinal Diseases
dc.subjectHeart Failure
dc.subjectHumans
dc.subjectInflammation
dc.subjectIntestinal Absorption
dc.subjectIntestines
dc.titleGastrointestinal changes associated to heart failure
dc.typeOtros


Este ítem pertenece a la siguiente institución